Site icon Fasano Underwriting

Advancing Frontiers in Metastatic Melanoma: Innovations, Treatments, and Improved Survival Outcomes

itm21stadmin
Advancing Frontiers in Metastatic Melanoma: Innovations, Treatments, and Improved Survival Outcomes

A team of scientists and medical professionals in laboratory coats review data and graphs on multiple monitors, focusing on analysis and research within a high-tech lab environment.

 

Research by Rahul Nawander, MD, Medical Director at Fasano Underwriting

Melanoma of the skin (cutaneous melanoma) is a malignant tumor originating from melanocytes, the skin cells responsible for producing melanin. While primarily occurring in the skin, melanoma can also arise in the eyes, ears, meninges, gastrointestinal tract, and mucosal surfaces such as the oral, genital, nasal, and sinus membranes. Cutaneous melanoma accounts for over 90% of all melanomas and is commonly observed in White populations [1].

The incidence of all skin cancers, including melanoma and non-melanoma skin cancers (NMSCs), has increased significantly in recent decades, outpacing many other cancers. This rise may partly reflect overdiagnosis due to more frequent skin screenings, biopsies, and the histopathological overcalling of melanocytic lesions that might otherwise remain benign [2]. Between 1982 and 2011, melanoma incidence rates doubled to quadrupled among individuals of European heritage [3]. According to the Centers for Disease Control and Prevention (CDC), the overall melanoma incidence rate in the U.S. between 2017 and 2021 was 21.8 per 100,000 people, with the highest rates among non-Hispanic White males (34.9 per 100,000) and the lowest among Black females (0.9 per 100,000) [4].

The common subtypes of cutaneous melanoma include [5]:

Rare variants include amelanotic melanoma, spitzoid melanoma, desmoplastic melanoma, and pigment-synthesizing melanoma (also known as animal-type melanoma).

Melanoma staging, detailed in the AJCC Cancer Staging Manual, Eighth Edition, provides a critical framework for diagnosis and prognosis. Simplified, the stages are as follows:

Approximately 85–90% of melanomas are diagnosed at a localized stage, with 70% being superficial spreading melanomas. For localized melanoma, prognosis is excellent, with survival rates comparable to the general population. A SEER database study [6] analyzing nearly 100,000 U.S. patients found no significant difference in life expectancy between individuals with localized melanoma and the general population. However, metastatic melanoma presents a starkly different outlook due to its aggressive nature and historically poor survival rates.

Treatment

Melanoma treatment varies by stage. Stages 0–3 melanomas are primarily managed with surgery, while Stage 4 metastatic melanoma requires systemic therapies like immunotherapy, targeted therapy, chemotherapy, radiation, or combination of these therapies. Surgery is typically not used in Stage 4 metastatic disease, as systemic therapies  are more effective in managing widespread disease.

Before 2011, chemotherapy was the primary systemic treatment, with dacarbazine being the only FDA-approved drug. However, since 2011, immunotherapy has revolutionized melanoma treatment, significantly improving survival rates. Melanoma was the first malignancy to benefit from immune checkpoint inhibitors (ICIs), which target checkpoint proteins such as CTLA-4, PD-1, PD-L1, and LAG-3. These proteins, expressed on T-cells, are exploited by cancer cells to evade immune responses. ICIs restore the anti-tumor activity of T-cells, enabling a sustained immune response. The FDA-approved ICIs for melanoma include:

  1. Ipilimumab (CTLA-4 antagonist)
  2. Nivolumab and pembrolizumab (PD-1 antagonists)
  3. Atezolizumab (PD-L1 antagonist)
  4. Relatlimab-rmbw (LAG-3 antagonist, approved in 2022).

Another recent advancement is talimogene laherparepvec (T-VEC or Imlygic®), an oncolytic virus therapy for advanced melanoma. T-VEC is a genetically modified herpes simplex virus designed to selectively infect and kill melanoma cells while stimulating both local and systemic immune responses.

Targeted therapy addresses the high prevalence of genetic mutations in melanoma, particularly in the BRAF, NRAS, and NF1 genes. By inhibiting these mutations, targeted therapies effectively halt tumor growth.

Prognosis & Survival

The prognosis for metastatic melanoma has improved dramatically with the introduction of immunotherapy and targeted therapy. A 2018 Canadian study [7] observed significant differences in two-year survival rates depending on the treatment modality: 6–17% for chemotherapy, 24–26% for targeted therapy, and 60–62% for immunotherapy. Among ICIs, PD-1 antagonists (nivolumab and pembrolizumab) showed the greatest survival benefit, followed by CTLA-4 antagonists (ipilimumab).

A 2022 Danish study [8] of 1,500 metastatic melanoma patients reported a 16% increase in 1-year survival and a 7% increase in 5-year survival between 2009–2013 and 2014–2018, see figure 1, below, underscoring the transformative impact of modern treatments.

Recent studies [9] have noted a fourfold improvement in median survival with immunotherapy, increasing from 18 months in 2018 to 72 months in 2022. Among patients achieving a complete response (no detectable disease at both the primary and metastatic sites), the 5-year survival rate was 86-89%, see figure 2. Approximately 70-75% of patients eligible for immunotherapy achieve a complete response.

Long-term benefits of immunotherapy persist even after treatment discontinuation. A 2021 study [10] found that 73-76% of patients who discontinued immunotherapy after a median treatment duration of 15.2 months (range: 0.7-42 months) maintained a complete response, with 4-year survival rates of 92–94%. For those achieving a partial response (no disease at primary location and stable disease at metastatic sites), 4-year survival rates were 80–82% [10] [11].

When compared to targeted therapy, patients responding to immunotherapy have 1.5-fold better survival rates [10].

Outlook
The outlook for metastatic melanoma continues to improve, driven by advancements in therapeutic strategies and ongoing research. Innovative approaches under exploration include combining multiple immune checkpoint inhibitors (ICIs), integrating immunotherapy with targeted therapies, utilizing these treatments as neoadjuvant options, and extending the use of immunotherapy to non-metastatic melanoma to enhance survival outcomes further. Currently, more than 322 clinical trials in the United States are dedicated to advancing melanoma treatments options.

At Fasano Associates, we specialize in providing evidence-based life expectancy estimates and life insurance underwriting decisions for complex cases. Our team of 18 Medical Directors, with over 550 combined years of clinical and insurance medicine experience, ensures reliable and informed evaluations for even the most challenging cases.

References

Exit mobile version